S-588410 administration could also contribute to changes in the TME from an immune desert to an inflamed tumor. Accordingly, transformation of cancer-immune phenotypes by S-588410 may have therapeutic potential when combined with anti-PD-(L)1 antibodies in patients [19, 20]. When we evaluated PD-L1 expression in tumor cells by IHC, ≥ 5% of tumor cells were PD-L1+ in ten out of 15 participants after vaccination (data not shown). Fujimoto et al. [21] previously described the equivalence of the PD-L1 antibodies 22C3 (indicated in combination with pembrolizumab) and SP263 (used in our study). If the efficacy of pembrolizumab is confirmed in patients with ≥ 5% PD-L1+ tumor cells characterized by 22C3 in KEYNOTE-181 [22], PD-L1 induction by S-588410 may support combination therapy with a PD-(L)1 antibody.
S-588410 administration could also contribute to changes in the TME from an immune desert to an inflamed tumor. Accordingly, transformation of cancer-immune phenotypes by S-588410 may have therapeutic potential when combined with anti-PD-(L)1 antibodies in patients [19, 20]. When we evaluated PD-L1 expression in tumor cells by IHC, ≥ 5% of tumor cells were PD-L1+ in ten out of 15 participants after vaccination (data not shown). Fujimoto et al. [21] previously described the equivalence of the PD-L1 antibodies 22C3 (indicated in combination with pembrolizumab) and SP263 (used in our study). If the efficacy of pembrolizumab is confirmed in patients with ≥ 5% PD-L1+ tumor cells characterized by 22C3 in KEYNOTE-181 [22], PD-L1 induction by S-588410 may support combination therapy with a PD-(L)1 antibody.
腫瘍へのTMEの変化にも寄与する可能性
S-588410による癌免疫表現型の変換は、治療可能性を有していてもよい
次のIRが楽しみすぎますね